Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage-Reference-Cited by-同舟云学术

Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

Published:2020-08-21 Issue:6506 Volume:369 Page:936-942
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Fluckiger Aurélie¹²^ORCID,Daillère Romain¹²³,Sassi Mohamed⁴^ORCID,Sixt Barbara Susanne⁵⁶⁷⁸⁹^ORCID,Liu Peng⁶⁷⁸⁹¹⁰^ORCID,Loos Friedemann⁶⁷⁸⁹¹⁰^ORCID,Richard Corentin¹¹¹²¹³^ORCID,Rabu Catherine¹⁴¹⁵^ORCID,Alou Maryam Tidjani¹²¹⁶,Goubet Anne-Gaëlle¹²^ORCID,Lemaitre Fabien¹³^ORCID,Ferrere Gladys¹²,Derosa Lisa¹²¹⁷^ORCID,Duong Connie P. M.¹²^ORCID,Messaoudene Meriem¹⁸,Gagné Andréanne¹⁸^ORCID,Joubert Philippe¹⁸^ORCID,De Sordi Luisa¹⁹²⁰^ORCID,Debarbieux Laurent¹⁹^ORCID,Simon Sylvain¹⁴¹⁵^ORCID,Scarlata Clara-Maria²¹^ORCID,Ayyoub Maha²¹^ORCID,Palermo Belinda²²^ORCID,Facciolo Francesco²³,Boidot Romain²⁴^ORCID,Wheeler Richard²⁵^ORCID,Boneca Ivo Gomperts²⁵^ORCID,Sztupinszki Zsofia²⁶^ORCID,Papp Krisztian²⁷^ORCID,Csabai Istvan²⁷^ORCID,Pasolli Edoardo²⁸^ORCID,Segata Nicola²⁹^ORCID,Lopez-Otin Carlos⁷⁸⁹¹⁰³⁰^ORCID,Szallasi Zoltan²⁶³¹³²³³^ORCID,Andre Fabrice³⁴³⁵^ORCID,Iebba Valerio¹²³⁶^ORCID,Quiniou Valentin³⁷³⁸^ORCID,Klatzmann David³⁷³⁸,Boukhalil Jacques¹⁶,Khelaifia Saber¹⁶,Raoult Didier¹⁶,Albiges Laurence¹³⁹,Escudier Bernard¹³⁹⁴⁰^ORCID,Eggermont Alexander¹⁴¹^ORCID,Mami-Chouaib Fathia⁴²,Nistico Paola²²²³^ORCID,Ghiringhelli François⁴³,Routy Bertrand¹⁸⁴⁴^ORCID,Labarrière Nathalie¹⁴¹⁵^ORCID,Cattoir Vincent⁴⁴⁵⁴⁶^ORCID,Kroemer Guido⁶⁷⁸⁹¹⁰^ORCID,Zitvogel Laurence¹²¹⁷⁴⁷^ORCID

Affiliation:

1. Gustave Roussy Cancer Campus (GRCC), Villejuif, France.

2. Institut National de la Santé et de la Recherche Médicale, U1015, Institut Gustave Roussy, Villejuif, France.

3. everImmune, Gustave Roussy Cancer Center, Villejuif, France.

4. Université Rennes 1, Laboratoire de Biochimie Pharmaceutique, Inserm U1230 - UPRES EA 2311, Rennes, France.

5. Laboratory for Molecular Infection Medicine Sweden, Umeå Centre for Microbial Research, Department of Molecular Biology, Umeå University, 90187, Umeå, Sweden.

6. Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, France.

7. Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.

8. INSERM U1138, Paris, France.

9. Université de Paris, Paris, France.

10. Sorbonne Université, Paris, France.

11. Research Platform in Biological Oncology, Dijon, France.

12. GIMI Genetic and Immunology Medical Institute, Dijon, France.

13. University of Burgundy-Franche Comté, Dijon, France.

14. CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.

15. LabEx IGO “Immunotherapy, Graft, Oncology,” Nantes, France.

16. UMR MEPHI, Aix-Marseille Université, IRD, AP-HM, Institut Hospitalo-Universitaire Méditerranée-Infection, 19-21 Boulevard Jean Moulin, 13385, Marseille cedex 05, France.

17. Université Paris-Saclay, Villejuif, F-94805, France.

18. Institut Universitaire de Cardiologie et de Pneumologie de Québec, Research Center and Department of Cytology and Pathology, Québec City, Québec, Canada.

19. Bacteriophage, Bacterium, Host Laboratory, Institut Pasteur, F-75015 Paris, France.

20. Sorbonne Université, Centre de Recherche Saint Antoine, INSERM UMRS_938, Paris, France.

21. Cancer Research Centre of Toulouse, INSERM UMR 1037, 31037 Toulouse, France; Université Toulouse III Paul Sabatier, 31330 Toulouse, France; Institut Universitaire du Cancer de Toulouse-Oncopole, 31100 Toulouse, France.

22. Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

23. Thoracic Surgery Unit, Department of Surgical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

24. Unit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.

25. Institut Pasteur, Unit Biology and Genetics of the Bacterial Cell Wall, Paris, France.

26. Computational Health Informatics Program (CHIP), Boston Children's Hospital, Boston, MA, USA.

27. Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Budapest, Hungary.

28. Department of Agricultural Sciences, University of Naples Federico II, Naples, Italy.

29. Department CIBIO, University of Trento, Trento, Italy.

30. Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.

31. Harvard Medical School, Boston, MA, USA.

32. Danish Cancer Society Research Center, Copenhagen, Denmark.

33. MTA-SE-NAP, Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis University, Budapest, Hungary.

34. Department of Cancer Medicine, Breast Cancer Committee, Gustave Roussy, Villejuif, France.

35. INSERM Unit 981, Gustave Roussy, Villejuif, France.

36. Department of Medical Sciences, University of Trieste, 34137 Trieste, Italy.

37. AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center in Biotherapy (CIC-BTi) and Immunology-Inflammation-Infectiology and Dermatology Department (3iD), F-75651, Paris, France.

38. Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), F-75651, Paris, France.

39. Department of Medical Oncology, Gustave Roussy, Villejuif, France.

40. INSERM U981, GRCC, Villejuif, France.

41. Princess Maxima Center, CS 3584 Utrecht, the Netherlands.

42. INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine - Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France.

43. Department of Medical Oncology, Center GF Leclerc, Dijon, France.

44. Division d'Hémato-Oncologie, Département de Médicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.

45. CHU de Rennes - Hôpital Ponchaillou, Service de Bactériologie-Hygiène Hospitalière, Rennes, France.

46. CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France.

47. Suzhou Institute for Systems Biology, Chinese Academy of Medical Sciences, Suzhou, China.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference52 articles.

1. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

2. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

3. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

4. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

5. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer;Frontiers in Immunology;2024-02-01

2. Glioblastoma vaccines: past, present, and opportunities;eBioMedicine;2024-02

3. Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors;Cancer Letters;2024-02

4. Integrating the gut microbiome and pharmacology;Science Translational Medicine;2024-01-31

5. Intratumoural microbiota: a new frontier in cancer development and therapy;Signal Transduction and Targeted Therapy;2024-01-10